Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8453183 | Journal of Bone Oncology | 2018 | 5 Pages |
Abstract
Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients with limb salvage was not inferior to that of amputees, and therefore, limb salvage has become the main surgical option for patients with osteosarcoma. The 5-year survival rate for osteosarcoma has plateaued. However, new advances in limb salvage therapy in osteosarcoma, including adjuvant chemotherapy, ablation techniques, bone transport techniques, and computer navigation techniques, are now available. This report summarizes the recent advances in limb salvage therapy for osteosarcoma over the past decade.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yichun Yang, Lei Han, Zewei He, Xiaojuan Li, Suping Yang, Jifei Yang, Ya Zhang, Dongqi Li, Yihao Yang, Zuozhang Yang,